Last Updated: November 8, 2026

CLINICAL TRIALS PROFILE FOR MITOXANTRONE HYDROCHLORIDE

« Back to Dashboard

All Clinical Trials for MITOXANTRONE HYDROCHLORIDE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002003 ↗	Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas	Completed	Lederle Laboratories	Phase 2	1969-12-31	To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
NCT00002259 ↗	Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma	Completed	Lederle Laboratories	Phase 2	1969-12-31	To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
NCT00002474 ↗	Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer	Completed	Loyola University	Phase 2	1991-02-01	RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MITOXANTRONE HYDROCHLORIDE

Condition Name

Chart
Table

Condition Name for MITOXANTRONE HYDROCHLORIDE
Intervention	Trials
Acute Myeloid Leukemia	53
Leukemia	50
Prostate Cancer	29
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MITOXANTRONE HYDROCHLORIDE
Intervention	Trials
Leukemia	182
Leukemia, Myeloid, Acute	148
Leukemia, Myeloid	134
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MITOXANTRONE HYDROCHLORIDE

Trials by Country

Map
Table

Trials by Country for MITOXANTRONE HYDROCHLORIDE
Location	Trials
China	149
Canada	140
Germany	64
Spain	56
Australia	56
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MITOXANTRONE HYDROCHLORIDE
Location	Trials
California	63
New York	55
Ohio	50
Illinois	49
Texas	48
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MITOXANTRONE HYDROCHLORIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MITOXANTRONE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	4
PHASE2	24
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MITOXANTRONE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	182
RECRUITING	77
Terminated	46
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MITOXANTRONE HYDROCHLORIDE

Sponsor Name

Chart
Table

Sponsor Name for MITOXANTRONE HYDROCHLORIDE
Sponsor	Trials
National Cancer Institute (NCI)	74
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	27
Fred Hutchinson Cancer Research Center	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MITOXANTRONE HYDROCHLORIDE
Sponsor	Trials
Other	497
Industry	193
NIH	75
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.